TCT-406 Clinical Impact of DAPT Cessation Within 12 Months of Drug-Eluting Stent Implantation in Caucasians and Minorities: Insights From the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study

Davide Cao,Roxana Mehran,Anastasios Roumeliotis,Rishi Chandiramani,Moritz Blum,Ridhima Goel,Samantha Sartori,John C. Wang,Islam Othman,Henry A. Liberman,Dominic J. Allocco,Paul Underwood,Wayne Batchelor

TCT-406 Clinical Impact of DAPT Cessation Within 12 Months of Drug-Eluting Stent Implantation in Caucasians and Minorities: Insights From the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study

2019

Davide Cao
Roxana Mehran
Anastasios Roumeliotis
Rishi Chandiramani
Moritz Blum
Ridhima Goel
Samantha Sartori
John C. Wang
Islam Othman
Henry A. Liberman
Dominic J. Allocco
Paul Underwood
Wayne Batchelor

Cessation of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) may increase the risk of recurrent ischemic events. Because patterns of DAPT adherence in minorities might be different than in Caucasians, this study evaluated the impact of DAPT cessation within 1 year of

Keywords:

Diabetes mellitus
Cardiology
Drug-eluting stent
Internal medicine
Medicine
Conventional PCI
Percutaneous coronary intervention

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations